Spots Global Cancer Trial Database for Study of XL114 in Subjects With Non-Hodgkin's Lymphoma
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Study of XL114 in Subjects With Non-Hodgkin's Lymphoma
Official Title: A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL114 Administered in Subjects With Non-Hodgkin's Lymphoma
Study ID: NCT05144347
Interventions
Study Description
Brief Summary: This is a Phase 1, non-randomized, open-label, dose-escalation and expansion study, evaluating the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary clinical antitumor activity of XL114 administered alone orally to subjects with Non-Hodgkin's Lymphoma (NHL). The objectives of the study also include determining the recommended dose (RD) and/or maximum tolerated dose (MTD) of XL114.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Exelixis Clinical Site #3, Tucson, Arizona, United States
Exelixis Clinical Site #1, Indianapolis, Indiana, United States
Exelixis Clinical #4, Pittsburgh, Pennsylvania, United States
Exelixis Clinical Site #2, Spokane, Washington, United States
Contact Details
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
